Influence of Preparation Methods on Physicochemical and Pharmacokinetic Properties of Co-amorphous Formulations: The Case of Co-amorphous Atorvastatin: Naringin

被引:32
|
作者
Nair, Athira [1 ]
Varma, Raghava [1 ]
Gourishetti, Karthik [2 ]
Bhat, Krishnamurthy [1 ]
Dengale, Swapnil [1 ]
机构
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmaceut Qual Assurance, Manipal 576104, Karnataka, India
[2] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Dept Pharmacol, Manipal 576104, India
关键词
Co-amorphous; Atorvastatin; Naringin; Ball milling; Solvent evaporation; Quench cooling; SOLID-STATE CHARACTERIZATION; IMPROVED PHYSICAL STABILITY; WATER-SOLUBLE DRUGS; DISSOLUTION RATE; COAMORPHOUS ATORVASTATIN; ENHANCED BIOAVAILABILITY; ENTHALPIC RELAXATION; BINARY-SYSTEMS; DOSAGE FORMS; AMINO-ACIDS;
D O I
10.1007/s12247-019-09381-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The goal of the study was to investigate the influence of processing methods on the physicochemical and pharmacokinetic properties of co-amorphous materials. Methods Co-amorphous formulations of atorvastatin (ATV) and naringin (NRG) in the molar ratio 1:1 were prepared by quench cooling (ANQC), solvent evaporation (ANSE), and ball milling (ANBM) and characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (XRPD), and Fourier transform infrared spectroscopy (FTIR). Further, the performance of prepared co-amorphous formulations was evaluated in vitro and in vivo. Results All processing methods yielded homogeneous co-amorphous formulation, which was confirmed by single glass transition (Tg) event and diffuse halo in DSC and XRPD, respectively. Irrespective of processing method employed, all co-amorphous formulations were found stable at 30 degrees C for 90 days in dry conditions (under vacuum). Significant improvement in the solubility of ATV was observed in ANQC and ANSE co-amorphous formulations, highest being 56-fold for the later. ATV from ANSE formulation showed highest drug release (97%), while surprisingly ANQC showed significantly lower ATV release as compared to the physical mixture. Amongst three preparation methods, solubility advantage of ANSE could translate into efficacious pharmacokinetic parameters, where the improvement in ATV exposure (AUC 0-t) and plasma concentration (Cmax) were found 4.5-fold and 7-fold, respectively, as compared to the physical mixture. Conclusion It was concluded that the preparation methods of co-amorphous formulations have a profound effect on physical properties like stability, physicochemical properties like solubility, dissolution rate, and pharmacokinetic properties like AUC and Cmax.
引用
收藏
页码:365 / 379
页数:15
相关论文
共 50 条
  • [41] Production of co-amorphous materials with therapeutic activity
    Bastos, Ana C.
    Pinto, Joao F.
    Fernandes, Ana I.
    ANNALS OF MEDICINE, 2018, 50 : S52 - S53
  • [42] Assessment of the stability of co-amorphous olanzapine in tablets
    da Costa, Nuno F.
    Pinto, Joao F.
    Fernandes, Ana I.
    ANNALS OF MEDICINE, 2021, 53 : S110 - S111
  • [43] Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media
    Heikkinen, A. T.
    DeClerck, L.
    Lobmann, K.
    Grohganz, H.
    Rades, T.
    Laitinen, R.
    PHARMAZIE, 2015, 70 (07): : 452 - 457
  • [44] Predictive identification of co-formers in co-amorphous systems
    Chambers, Luke I.
    Grohganz, Holger
    Palmelund, Henrik
    Lobmann, Korbinian
    Rades, Thomas
    Musa, Osama M.
    Steed, Jonathan W.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 157
  • [45] Breaking barriers: enhancing solubility and dissolution of efonidipine using co-amorphous formulations
    Jadav, Shreyansh
    Dudhat, Kiran
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 5713 - 5727
  • [46] Preparation and Characterization of Lutein Co-Amorphous Formulation with Enhanced Solubility and Dissolution
    Song, Xuening
    Luo, Yingting
    Zhao, Wenduo
    Liu, Simiao
    Wang, Yuzhuo
    Zhang, Hao
    FOODS, 2024, 13 (13)
  • [47] Co-Amorphous Formulations of Furosemide with Arginine and P-Glycoprotein Inhibitor Drugs
    Ruponen, Marika
    Kettunen, Konsta
    Santiago Pires, Monica
    Laitinen, Riikka
    PHARMACEUTICS, 2021, 13 (02) : 1 - 18
  • [48] Investigation of the preparation, characterization, and whitening activity of co-amorphous glabridin and oxymatrine
    Liang, Peiyi
    Hu, Yi
    Wang, Zhuxian
    Guo, Yinglin
    Chen, Hongkai
    Jiang, Cuiping
    Zeng, Quanfu
    Shen, Chunyan
    Wu, Yufan
    Liu, Li
    Yi, Yankui
    Zhu, Hongxia
    Yang, Zhijun
    Liu, Qiang
    CRYSTENGCOMM, 2023, 25 (45) : 6252 - 6265
  • [49] Development of Co-Amorphous Loratadine-Citric Acid Orodispersible Drug Formulations
    Redai, Emoke Margit
    Sipos, Emese
    Vlad, Robert Alexandru
    Antonoaea, Paula
    Todoran, Nicoleta
    Ciurba, Adriana
    PROCESSES, 2022, 10 (12)
  • [50] Considerations on the Kinetic Processes in the Preparation of Ternary Co-Amorphous Systems by Milling
    Wang, Yixuan
    Rades, Thomas
    Grohganz, Holger
    PHARMACEUTICS, 2023, 15 (01)